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Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disorder characterized by generalized seizures
in the first hours of life and responding only to pyridoxine hydrochloride. The pathogenesis of PDE is unknown,
but an alteration in the binding of pyridoxal 5-phosphate to glutamic acid decarboxylase (GAD) has been postulated
in patients with PDE. Results are reported for genetic linkage analyses in four families with consanguineous parents
and in one family with nonconsanguineous parents. The GAD1 (2q31) and GAD2 genes (10p23) were tested and
excluded. A genomewide search was subsequently performed, using microsatellite markers at an average distance
of 10 cM, and the search revealed linkage of the disease-causing gene to markers on chromosome 5q31.2-q31.3
(maximum LOD score [Zmax] 8.43 at recombination fraction [v] 0 and at at loci D5S2017 andZ p 7.58 vp 0max
D5S1972, respectively). A recombination event, between loci D5S638 and D5S463, in one family defined the distal
boundary, and a second recombination event between loci D5S2011 and D5S2017 in another family defined the
proximal boundary of the genetic interval encompassing the PDE gene (5.1 cM). Ongoing studies may lead to the
identification of the disease-causing gene.
Pyridoxine-dependent epilepsy (PDE [MIM 226100]) is
a rare autosomal recessive disorder characterized by a
combination of various seizure types that usually occurs
in the first hours of life and is unresponsive to standard
anticonvulsants, responding only to immediate admin-
istration of pyridoxine hydrochloride (vitamin B6)
(Hunt et al. 1954; Waldinger and Berg 1964; Nabbout
et al. 1999). The dependence is permanent, and the in-
terruption of daily pyridoxine supplementation leads to
the recurrence of seizures. The pathogenesis of vitamin
B6–dependent seizures is unknown, but some research-
ers have postulated that a reduced synthesis of g-amino-
butyric acid (GABA), resulting from diminished activity
of the glutamic acid decarboxylase (GAD), could be re-
sponsible for the lowered seizure threshold in vitamin
B6–dependent patients (Scriver andWhelan 1969; Yosh-
ida et al. 1971). GAD requires pyridoxal 5-phosphate
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(PLP) as a coenzyme for activity, and an alteration in
the binding of PLP to GAD has also been postulated in
vitamin B6–dependent patients (Scriver and Whelan
1969; Scriver and Gibson 1995). Biochemical findings
in affected individuals included (a) decreased levels of
GABA in the brain and cerebrospinal fluid (CSF), (b)
increased levels of glutamate in CSF and the cerebral
cortex, and (c) decreased levels of PLP in the frontal
cortex (Lott et al. 1978; Baumeister et al. 1994). Study
of GAD activity in the kidney of an affected proband
has revealed a complete deficiency of GABA synthesis,
with a restoration to normal levels when the coenzyme
is added (Yoshida et al. 1971).
In this article, we report the genetic linkage analysis
of four families with consanguineous parents and of one
family with nonconsanguineous parents. The clinical
and electroencephalographic features of these families
have been reported elsewhere (Nabbout et al. 1999). The
diagnosis of PDE was based on the presence of gener-
alized seizures that responded only to vitamin B6 ad-
ministration in the first days of life. The families were
of Turkish (family 1), French (family 2),Maurician (fam-
ily 3), and Algerian ancestries (families 4 and 5).
DNA extraction and microsatellite analyses were per-
formed as described elsewhere (Belin et al. 1998). The
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Table 1
Two-Point LOD Scores for Linkage of the Pyridoxine-Dependent Epilepsy Locus
to Chromosome 5q31 Markers
MARKER
GENETIC
DISTANCEa
(cM)
LOD SCORE AT v p
.00 .05 .10 .15 .20 .30 Zmax v
D5S658 2.7 99 5.14 4.80 4.22 3.55 2.13 5.14 .05
D5S2017 0 8.43 7.31 6.20 5.10 4.05 2.15 8.43 .00
D5S1972 .2 7.58 6.57 5.58 4.60 3.66 1.97 7.58 .00
D5S402 .8 99 2.36 2.06 1.67 1.28 .61 2.36 .05
D5S436 1.9 99 5.02 4.48 3.82 3.12 1.79 5.02 .05
a From locus D5S2017 according to the Ge´ne´thon map.
Figure 1 Pedigrees and genotype data for markers spanning the PDE-locus interval. Markers are given in order, from the p telomere to
the q telomere. The region of homozygosity is blackened.
homozygosity-mapping strategy in consanguineous fam-
ilies was based on the assumption that affected individ-
uals from the same kindred are homozygous by descent,
for the disease-causing gene mutation. Microsatellite
DNA markers from the entire genome were chosen from
the Ge´ne´thon map (Dib et al. 1996), and two-point link-
age analyses using the MLINK option of the linkage
package (Lathrop et al. 1985) were performed. We as-
sumed the frequency of the disease allele to be .001 and
set the penetrance at 100%, assuming an autosomal re-
cessive mode of inheritance. We took into account the
inbreeding loops, but allele frequencies were not avail-
able in the populations studied.
We first tested and excluded the GAD1 (2q31) and
GAD2 (10p.23) genes, because these genes were re-
garded a priori as excellent candidates (data not shown).
Then, we performed a genomewide search, with the
use of microsatellite markers at an average distance of
10 cM, and found linkage of the disease-causing gene
to markers on chromosome 5q31.2-q31.3 (maximum
LOD score [Zmax] 8.43 at recombination fraction [v] 0
and at , for markers AFMb074xg1Z p 7.58 vp 0max
and AFMa190bx1, respectively, at loci D5S2017 and
D5S1972, respectively) (table 1). The probands were
homozygotes at loci D5S2017, D5S1972, D5S402,
D5S2099, D5S436, D5S643, D5S2033, and D5S638, in
all consanguineous families. In family 5, affected indi-
viduals were genoidentical but were different from un-
affected sibs. A recombination event between loci
D5S2011 and D5S2017 in family 2 defined the prox-
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imal boundary of the genetic interval encompassing
the disease-causing gene. In addition, a second recom-
bination event, between D5S638 and D5S463, in family
4 defined the distal boundary of the genetic interval en-
compassing the PDE gene (5.1 cM) (fig. 1).
The physical map of the 5q31.3-qter has been re-
ported by Kostrzewa et al. (1998). More than 50 genes
and 1130 expressed sequence tags have been assigned
to distal chromosome 5q. Among them, the GABA-A–
receptor gene cluster and the glutamate receptor gene
(GRIA1) could be regarded as candidate genes in epi-
lepsy; however, they are reported to map to chromo-
somes 5q33 and 5q32, respectively—that is, outside the
genetic interval defined by our study (GeneMap’99). At
least three genes mapped to the critical region—namely,
the fibroblast growth factor-1, glucocorticoid receptor,
and KIAAO555 genes. Whether any of these genes is
involved in PDE is under investigation.
In conclusion, we have excluded the primary involve-
ment of GAD in the pathogenesis of PDE and have found
linkage of the disease-causing gene to the 5q31 region,
in the vicinity of a GABA-A–receptor gene cluster and
of a glutamate-receptor gene, but both genes were ex-
cluded by our linkage data. We hope that ongoing stud-
ies will identify the disease-causing gene and help to
explain the pathogenesis of pyridoxine dependence in
PDE and, more generally, help to elucidate the patho-
genesis of epileptic seizures in humans.
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